- Home
- EDSA vs CMMB Comparison
EDSA vs CMMB Comparison
Compare EDSA & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDSA
- CMMB
- Stock Information
- Founded
- EDSA 2015
- CMMB 2004
- Country
- EDSA Canada
- CMMB Israel
- Employees
- EDSA N/A
- CMMB N/A
- Industry
- EDSA Biotechnology: Pharmaceutical Preparations
- CMMB Biotechnology: Pharmaceutical Preparations
- Sector
- EDSA Health Care
- CMMB Health Care
- Exchange
- EDSA Nasdaq
- CMMB Nasdaq
- Market Cap
- EDSA 6.1M
- CMMB N/A
- IPO Year
- EDSA N/A
- CMMB N/A
- Fundamental
- Price
- EDSA $1.73
- CMMB $1.68
- Analyst Decision
- EDSA Strong Buy
- CMMB Strong Buy
- Analyst Count
- EDSA 1
- CMMB 3
- Target Price
- EDSA $21.00
- CMMB $7.33
- AVG Volume (30 Days)
- EDSA 30.6K
- CMMB 87.3K
- Earning Date
- EDSA 02-07-2025
- CMMB 11-14-2024
- Dividend Yield
- EDSA N/A
- CMMB N/A
- EPS Growth
- EDSA N/A
- CMMB N/A
- EPS
- EDSA N/A
- CMMB N/A
- Revenue
- EDSA N/A
- CMMB N/A
- Revenue This Year
- EDSA N/A
- CMMB N/A
- Revenue Next Year
- EDSA N/A
- CMMB N/A
- P/E Ratio
- EDSA N/A
- CMMB N/A
- Revenue Growth
- EDSA N/A
- CMMB N/A
- 52 Week Low
- EDSA $1.55
- CMMB $0.45
- 52 Week High
- EDSA $5.99
- CMMB $2.55
- Technical
- Relative Strength Index (RSI)
- EDSA 31.51
- CMMB 52.44
- Support Level
- EDSA $1.73
- CMMB $1.53
- Resistance Level
- EDSA $1.99
- CMMB $1.71
- Average True Range (ATR)
- EDSA 0.19
- CMMB 0.11
- MACD
- EDSA 0.02
- CMMB -0.01
- Stochastic Oscillator
- EDSA 18.00
- CMMB 39.47
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB01, is a non-steroidal, anti-inflammatory treatment for chronic allergic contact dermatitis. The company operates in a single segment: research and development, manufacturing, and commercialization of innovative pharmaceutical products. The company's EB05 candidate is a monoclonal antibody therapy for hospitalized COVID-19 patients.